Wynn Resorts, Limited (WYNN) Forms $192.51 Double Top; 15 Analysts Bullish Aerie Pharmaceuticals, Inc. (AERI)

Wynn Resorts, Limited (NASDAQ:WYNN) Logo

Among 15 analysts covering Aerie Pharmaceuticals (NASDAQ:AERI), 15 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aerie Pharmaceuticals had 53 analyst reports since August 7, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, February 28 by Cantor Fitzgerald. Cowen & Co maintained the stock with “Buy” rating in Tuesday, September 26 report. The stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) earned “Buy” rating by Canaccord Genuity on Wednesday, January 24. Stifel Nicolaus maintained it with “Buy” rating and $80.0 target in Tuesday, January 2 report. The stock has “Buy” rating by Needham on Friday, September 15. The company was maintained on Wednesday, November 4 by RBC Capital Markets. Canaccord Genuity maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) rating on Wednesday, August 16. Canaccord Genuity has “Buy” rating and $65.0 target. Cantor Fitzgerald maintained the shares of AERI in report on Friday, August 7 with “Buy” rating. The stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has “Buy” rating given on Tuesday, September 20 by H.C. Wainwright. The stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) earned “Buy” rating by Stifel Nicolaus on Thursday, September 17. See Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) latest ratings:

09/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $78.0000 Maintain
09/05/2018 Broker: Mizuho Rating: Buy New Target: $77.0000 Maintain
08/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $86.0000 Maintain
29/03/2018 Broker: Mizuho Rating: Buy New Target: $87.0000 Maintain
01/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $78.0 Maintain
28/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $86.0 Maintain
16/02/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy New Target: $78 Reinitiate
26/01/2018 Broker: Seaport Global Rating: Buy New Target: $78 Initiates Coverage On
24/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $86.0 Maintain
02/01/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $80.0 Maintain

Wynn Resorts, Limited (WYNN) formed double top with $200.21 target or 4.00% above today’s $192.51 share price. Wynn Resorts, Limited (WYNN) has $20.88B valuation. The stock increased 1.23% or $2.34 during the last trading session, reaching $192.51. About 1.60M shares traded. Wynn Resorts, Limited (NASDAQ:WYNN) has risen 55.02% since May 17, 2017 and is uptrending. It has outperformed by 43.47% the S&P500.

Analysts await Wynn Resorts, Limited (NASDAQ:WYNN) to report earnings on July, 24. They expect $2.05 EPS, up 73.73% or $0.87 from last year’s $1.18 per share. WYNN’s profit will be $222.34M for 23.48 P/E if the $2.05 EPS becomes a reality. After $2.30 actual EPS reported by Wynn Resorts, Limited for the previous quarter, Wall Street now forecasts -10.87% negative EPS growth.

Among 29 analysts covering Wynn Resorts (NASDAQ:WYNN), 17 have Buy rating, 1 Sell and 11 Hold. Therefore 59% are positive. Wynn Resorts has $23000 highest and $54 lowest target. $160.42’s average target is -16.67% below currents $192.51 stock price. Wynn Resorts had 99 analyst reports since July 31, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Thursday, September 3 by Argus Research. The firm earned “Neutral” rating on Friday, March 11 by Sterne Agee CRT. As per Friday, July 29, the company rating was downgraded by CLSA. The firm has “Buy” rating by CFRA given on Wednesday, February 7. The stock of Wynn Resorts, Limited (NASDAQ:WYNN) earned “Hold” rating by Bank of America on Wednesday, January 31. Telsey Advisory Group maintained Wynn Resorts, Limited (NASDAQ:WYNN) rating on Thursday, November 19. Telsey Advisory Group has “Market Perform” rating and $68 target. Gabelli initiated the stock with “Buy” rating in Tuesday, October 27 report. The stock has “Overweight” rating by JP Morgan on Tuesday, March 27. The rating was maintained by Stifel Nicolaus with “Hold” on Tuesday, January 23. Morgan Stanley maintained Wynn Resorts, Limited (NASDAQ:WYNN) rating on Friday, October 13. Morgan Stanley has “Overweight” rating and $158 target.

Investors sentiment increased to 1.23 in Q4 2017. Its up 0.11, from 1.12 in 2017Q3. It is positive, as 37 investors sold Wynn Resorts, Limited shares while 149 reduced holdings. 75 funds opened positions while 153 raised stakes. 71.04 million shares or 2.78% less from 73.07 million shares in 2017Q3 were reported. Usa Finance Portformulas owns 1.96% invested in Wynn Resorts, Limited (NASDAQ:WYNN) for 48,838 shares. 2,827 were reported by Institute For Wealth Mngmt Ltd Liability Co. Dimensional Fund L P holds 0.02% or 321,069 shares. Blair William Company Il invested in 0% or 4,172 shares. Manufacturers Life Insur The stated it has 0.02% in Wynn Resorts, Limited (NASDAQ:WYNN). Coastline Comm holds 0.1% or 3,760 shares. Paloma Prtn Mgmt has 11,184 shares. 12,932 are owned by Cibc Asset Mngmt. Us National Bank De has invested 0.03% in Wynn Resorts, Limited (NASDAQ:WYNN). Cibc World Markets Inc owns 5,394 shares. Vanguard Grp owns 0.07% invested in Wynn Resorts, Limited (NASDAQ:WYNN) for 8.86M shares. Ameritas Invest Prtn accumulated 0.03% or 3,626 shares. Amalgamated Financial Bank has invested 0.05% of its portfolio in Wynn Resorts, Limited (NASDAQ:WYNN). Cornerstone Advsrs accumulated 0.02% or 157 shares. First Foundation Advisors holds 0.16% of its portfolio in Wynn Resorts, Limited (NASDAQ:WYNN) for 17,254 shares.

Since March 21, 2018, it had 0 insider purchases, and 5 selling transactions for $2.15 billion activity. Shares for $3.53 million were sold by MADDOX MATT. Another trade for 10,000 shares valued at $1.92 million was made by MILLER ROBERT JOS on Wednesday, May 2. On Wednesday, March 21 the insider WYNN STEPHEN A sold $738.90M.

More important recent Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) news were published by: Benzinga.com which released: “Benzinga Pro’s 5 Stocks To Watch Today” on May 15, 2018, also Globenewswire.com published article titled: “Investor Expectations to Drive Momentum within Roper Technologies, Inter Parfums, SunCoke Energy Partners, Aerie …”, Benzinga.com published: “Benzinga’s Daily Biotech Pulse: Valeant Earnings, Lipocine’s FDA Watch, Invivo CFO Departure” on May 08, 2018. More interesting news about Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) was released by: Businesswire.com and their article: “Aerie Pharmaceuticals to Announce First Quarter 2018 Financial Results and Host Conference Call on Tuesday, May 8 …” with publication date: April 26, 2018.

Investors sentiment decreased to 1.2 in 2017 Q4. Its down 0.53, from 1.73 in 2017Q3. It turned negative, as 23 investors sold Aerie Pharmaceuticals, Inc. shares while 48 reduced holdings. 21 funds opened positions while 64 raised stakes. 34.86 million shares or 1.29% more from 34.42 million shares in 2017Q3 were reported. Moreover, Polar Cap Ltd Liability Partnership has 0.06% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 100,000 shares. Kazazian Asset Limited Company holds 0.76% or 12,466 shares in its portfolio. Hanseatic Mngmt Svcs Inc, a New Mexico-based fund reported 16 shares. Prelude Mgmt Limited Liability Company reported 31,967 shares. Macquarie Grp Incorporated Limited reported 52,620 shares stake. Parallax Volatility Advisers L P reported 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Aqr Management Limited Liability Com has invested 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Federated Invsts Pa reported 9,537 shares. Dafna Capital Mngmt Ltd Liability Company has 116,770 shares for 3.76% of their portfolio. Jpmorgan Chase Comm, a New York-based fund reported 19,570 shares. Creative Planning invested in 0% or 3,600 shares. State Board Of Administration Of Florida Retirement Sys has invested 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Tocqueville Asset Management Lp owns 147,570 shares. First Mercantile Com owns 6,787 shares. Citigroup invested 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI).

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. The company has market cap of $2.02 billion. The Company’s lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It currently has negative earnings. The firm is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension.

The stock increased 1.59% or $0.8 during the last trading session, reaching $51.2. About 224,990 shares traded. Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has risen 16.25% since May 17, 2017 and is uptrending. It has outperformed by 4.70% the S&P500.

Wynn Resorts, Limited (NASDAQ:WYNN) Institutional Positions Chart